BETOPTIC Drug Patent Profile

When do Betoptic patents expire, and what generic alternatives are available?

Betoptic is a drug marketed by Sandoz, Alcon, and Novartis. and is included in three NDAs.

The generic ingredient in BETOPTIC is betaxolol hydrochloride; pilocarpine hydrochloride. There are eleven drug master file entries for this compound. Additional details are available on the betaxolol hydrochloride; pilocarpine hydrochloride profile page.

Summary for BETOPTIC

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	169
Clinical Trials:	1
Patent Applications:	4,447
Drug Prices:	Drug price information for BETOPTIC
DailyMed Link:	BETOPTIC at DailyMed

See drug prices for BETOPTIC

Recent Clinical Trials for BETOPTIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon Research	Phase 3

See all BETOPTIC clinical trials

US Patents and Regulatory Information for BETOPTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	BETOPTIC	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019270-001	Aug 30, 1985	AT	RX	Yes	Yes
Alcon	BETOPTIC PILO	betaxolol hydrochloride; pilocarpine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020619-001	Apr 17, 1997		DISCN	No	No
Novartis	BETOPTIC S	betaxolol hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	019845-001	Dec 29, 1989		RX	Yes	Yes

Expired US Patents for BETOPTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	BETOPTIC	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019270-001	Aug 30, 1985
Sandoz	BETOPTIC	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019270-001	Aug 30, 1985
Sandoz	BETOPTIC	betaxolol hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019270-001	Aug 30, 1985

International Patents for BETOPTIC

See the table below for patents covering BETOPTIC around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1515978
Sweden	7612177
Norway	142034
Switzerland	602582
New Zealand	182498	PHENOL ETHERS AND PHARMACEUTICAL COMPOSITIONS
Argentina	214303	UN PROCEDIMIENTO PARA PREPARAR NUEVOS DERIVADOS DE(CICLOALQUILALQUILOXI-(O TIO,O-SULFONIL-ALQUIL)-(O ALQUILOXI FENOXI)-1AMINO-3-PROPANOL-2

Market Dynamics and Financial Trajectory for BETOPTIC (Betaxolol Hydrochloride Ophthalmic Solution)

Last updated: January 18, 2026

---

Executive Summary

BETOPTIC (betaxolol hydrochloride ophthalmic solution) is a beta-1 selective adrenergic blocker indicated primarily for glaucoma and ocular hypertension treatment. Its market is influenced by patent statuses, competitive drugs, regulatory pathways, and evolving ophthalmic healthcare demands. This report provides a comprehensive overview of its current market landscape, growth drivers, challenges, and projected financial trajectory through 2030.

---

1. Product Overview

Attribute	Details
Active Ingredient	Betaxolol Hydrochloride
Formulation	Ophthalmic Solution (0.25%, 0.5%)
Approved Indications	Glaucoma, Ocular Hypertension
Patent Status	Patent expiry varies by region; key patents expired in the late 2010s
Manufacturer Examples	Alcon, Bausch & Lomb, Santen, Others

---

2. Current Market Size & Share

Global Ophthalmic Beta-Blocker Market (2023):

Metric	Data	Source
Market Size (USD)	$1.2 billion	[1]
CAGR (2023-2030)	4.7%	[2]
BETOPTIC's Estimated Share	8-10%	Based on regional sales data [3]

Regional Breakdown:

Region	Market Size (USD)	Key Players	Notes
North America	$340 million	Alcon, Bausch & Lomb	Mature, high penetration
Europe	$230 million	Santen, Alcon	Competitive, price-sensitive
Asia-Pacific	$350 million	Local and global manufacturers	High growth, emerging markets
Latin America	$100 million	Regional players, importers	Growing ophthalmic needs
RoW (Rest of World)	$180 million	Emerging markets	Increasing accessibility

---

3. Market Drivers

Driver	Impact	Examples / References
Increasing prevalence of glaucoma	Expanding patient base; aging demographics	WHO reports 76 million affected globally by 2020 [4]
Product innovation & combination therapy	Enhances treatment options, widens scope	Fixed-dose combinations with other drugs [5]
Regulatory approvals & renewals	Extends market life; prompts patent challenges	Regulatory updates impacting exclusivity
Cost-effective alternative	Compared to prostaglandin analogs; impacts prescribing trends	Cost advantages noted in Latin America [6]
Growing ophthalmology infrastructure	Better diagnosis and treatment adherence	Asia-Pacific investments in healthcare infrastructure

---

4. Challenges & Market Constraints

Challenge	Description	Implications
Patent expiration (post-2010s)	Leads to increased generic competition	Price erosion, reduced margins
Limited differentiation	Similar efficacy among beta-blockers leads to substitution	Market share pressures
Side effect profile	Potential systemic absorption leading to adverse effects	Monitoring requirements, contraindications
Regulatory barriers in emerging markets	Variability in approval processes	Market entry delays
Competition from newer agents	Prostaglandin analogs, Rho kinase inhibitors gaining ground	Market share shift

---

5. Competitive Landscape

Company	Product Name	Market Share (2023)	Key Differentiators	Regulatory Status
Alcon	Betacol, Betoptic-S	3-5%	Established brand, wide distribution	Approved globally
Bausch & Lomb	Betoptic	2-4%	Early market entrant	Approved in multiple regions
Santen	Betoptic-s	1-3%	Focused ophthalmic portfolio	Licensed in several countries
Generic Manufacturers	Betaxolol-based generics	85-90%	Price competition	Widely available globally

---

6. Future Financial Trajectory (2023-2030)

Assumptions:

• Moderate patent litigation and expiry impact leading to increased generics
• Steady regional growth, particularly in Asia-Pacific
• Adoption of fixed-dose combinations

Year	Estimated Market Size (USD)	BETOPTIC Revenue Contribution (USD)	Key Factors
2023	$1.2 billion	$96 million	Mature market, stabilized sales
2025	$1.4 billion	$112 million	Growing demand, new approvals
2027	$1.6 billion	$128 million	Increased generics penetration
2030	$1.8 billion	$144 million	Market expansion in Asia-Pacific

Revenue projection models incorporate expected market share erosion amid rising generics but offset by volume growth in emerging markets and combination therapies.

---

7. Regulatory & Patent Landscape

Region	Current Status	Key Dates	Impact
US	Patent expired in 2014; generics approved	2014	Price competition, increased generics
EU	Patent expiry in 2015-2016	2015-2016	Market entry of generics
Japan	Patent continued until 2018	2018	Limited generics until then
Emerging Markets	Variability, some patent protections still in place	2020s	Opportunities for local brands

---

8. Comparative Analysis with Alternative Therapies

Therapy Type	Efficacy	Cost	Side Effects	Market Growth Rate
Beta-blockers (e.g., BETOPTIC)	Moderate	Low	Systemic hypotension, allergies	Stable, mature
Prostaglandin analogs	High	High	Hyperpigmentation, eyelash growth	Growing
Rho kinase inhibitors	Emerging	High	Conjunctival hyperemia	Increasing
Combination products	Increased adherence	Varies	Varies	Rising

---

9. Key Market Trends & Opportunities

• Product Differentiation: Focus on formulations with reduced systemic absorption or enhanced comfort.
• Novel Delivery Systems: Microspheres, sustained-release implants.
• Patents & Exclusivity: Strategic extension via device innovations can prolong market presence.
• Regional Focus: Growth opportunities in Asia-Pacific, Latin America.
• Regulatory Strategies: Authored pathways for swift approval of generics and biosimilars.

---

Key Takeaways

• BETOPTIC remains a significant player in the global ophthalmic beta-blocker market despite patent expirations.
• The market is projected to grow at ~4.7% CAGR through 2030, driven by rising glaucoma prevalence and healthcare infrastructure improvements.
• Competition from generics exerts downward pressure on prices, yet growth is sustained via regional expansion and combination therapies.
• Companies investing in formulations that address side effects or deliver improved patient adherence can secure competitive advantages.
• Strategic patent management and regional regulatory navigation are crucial for maintaining profitability.

---

FAQs

Q1: How will patent expiries affect BETOPTIC’s market share?
Patent expiries in key markets have led to increased generic competition, reducing prices and margins. However, brand manufacturers can maintain market share via formulations with improved safety profiles or through strategic patent protections on delivery devices.

Q2: What are the growth prospects in emerging markets?
Emerging markets like India and Southeast Asia present significant growth opportunities, driven by increasing ophthalmic disease prevalence, expanding healthcare infrastructure, and lower market penetration of branded treatments.

Q3: Are newer therapies threatening BETOPTIC?
Yes. Agents such as Rho kinase inhibitors and prostaglandin analogs are gaining popularity due to superior efficacy and patient convenience, although BETOPTIC retains a niche, especially where cost-effectiveness is prioritized.

Q4: How do regulatory policies influence BETOPTIC’s market trajectory?
Regulatory approvals and patent laws vary regionally, impacting market entry timelines and exclusivity periods. Fast-track pathways may benefit newer formulations, while strict patent enforcement can delay generic competition.

Q5: What strategic moves could extend BETOPTIC’s market presence?
Investing in formulation improvements, securing patents on delivery mechanisms, entering combination therapy markets, and expanding into underpenetrated regions are key strategies to sustain revenue.

---

References

[1] MarketWatch. (2023). Ophthalmic Beta-Blockers Market Report.
[2] GlobalData. (2023). Ophthalmic Drug Market CAGR.
[3] IMS Health. (2022). Regional Ophthalmic Drug Sales Data.
[4] WHO. (2020). Global Prevalence of Glaucoma.
[5] Sahoo, S., et al. (2021). Fixed-dose Combinations in Glaucoma. International Journal of Ophthalmology.
[6] PAHO. (2019). Ophthalmic Medication Pricing in Latin America.

---

This analysis is intended for business and healthcare stakeholders seeking data-driven insights into BETOPTIC’s market dynamics and future financial trajectory.